MX2007006635A - Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion. - Google Patents

Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.

Info

Publication number
MX2007006635A
MX2007006635A MX2007006635A MX2007006635A MX2007006635A MX 2007006635 A MX2007006635 A MX 2007006635A MX 2007006635 A MX2007006635 A MX 2007006635A MX 2007006635 A MX2007006635 A MX 2007006635A MX 2007006635 A MX2007006635 A MX 2007006635A
Authority
MX
Mexico
Prior art keywords
release rate
rate controlling
hiv integrase
controlling composition
pharmaceutical formulation
Prior art date
Application number
MX2007006635A
Other languages
English (en)
Spanish (es)
Inventor
Nazaneen Pourkavoos
James R Ney
Maria T Cruanes
Yunhui Wu
Saurabh A Palkar
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007006635(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MX2007006635A publication Critical patent/MX2007006635A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2007006635A 2004-12-03 2005-12-02 Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion. MX2007006635A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63294404P 2004-12-03 2004-12-03
PCT/US2005/043727 WO2006060711A2 (en) 2004-12-03 2005-12-02 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition

Publications (1)

Publication Number Publication Date
MX2007006635A true MX2007006635A (es) 2007-06-19

Family

ID=36118082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006635A MX2007006635A (es) 2004-12-03 2005-12-02 Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.

Country Status (16)

Country Link
US (1) US8852632B2 (cg-RX-API-DMAC7.html)
EP (2) EP2586444B1 (cg-RX-API-DMAC7.html)
JP (1) JP5228488B2 (cg-RX-API-DMAC7.html)
KR (1) KR101351059B1 (cg-RX-API-DMAC7.html)
CN (1) CN101068550B (cg-RX-API-DMAC7.html)
AU (1) AU2005311652B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518781A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588445C (cg-RX-API-DMAC7.html)
ES (1) ES2755273T3 (cg-RX-API-DMAC7.html)
IL (1) IL183615A (cg-RX-API-DMAC7.html)
MX (1) MX2007006635A (cg-RX-API-DMAC7.html)
NO (1) NO20073405L (cg-RX-API-DMAC7.html)
NZ (1) NZ555120A (cg-RX-API-DMAC7.html)
RU (1) RU2382648C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006060711A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703866B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101068533B (zh) * 2004-12-03 2011-04-27 默沙东公司 含有抗成核剂的药物组合物
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CA2588466A1 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
WO2009009531A2 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives for the treatment of hiv infections
JP6122639B2 (ja) * 2009-10-26 2017-04-26 メルク・シャープ・エンド・ドーム・コーポレイション インテグラーゼ阻害剤を含有する固形医薬組成物
US8987272B2 (en) * 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
ES2450944T3 (es) * 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
WO2014030172A2 (en) * 2012-08-23 2014-02-27 Hetero Research Foundation Pharmaceutical formulations of rufinamide
US9763934B2 (en) * 2014-03-05 2017-09-19 Professional Compounding Centers Of America Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
US20210290548A1 (en) * 2018-06-06 2021-09-23 Merck Sharp & Dohme Corp. Formulations of raltegravir

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56992C2 (uk) * 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
CN100400042C (zh) * 1999-12-03 2008-07-09 聚合化学股份公司 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物
PL366998A1 (en) * 2001-05-03 2005-02-07 F.Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
CN1700918B (zh) * 2001-10-26 2011-06-08 P·安杰莱蒂分子生物学研究所 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
CA2463975A1 (en) * 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
AU2003220186A1 (en) * 2002-04-10 2003-10-27 Merck And Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
BR0317749A (pt) * 2002-12-27 2005-11-22 Angeletti P Ist Richerche Bio Composto, composição farmacêutica, e, uso de um composto
DE602004031767D1 (de) 2003-12-31 2011-04-21 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
CN101068533B (zh) * 2004-12-03 2011-04-27 默沙东公司 含有抗成核剂的药物组合物

Also Published As

Publication number Publication date
KR20070085695A (ko) 2007-08-27
JP2008521932A (ja) 2008-06-26
WO2006060711A2 (en) 2006-06-08
ES2755273T3 (es) 2020-04-22
IL183615A (en) 2013-01-31
EP1904067A2 (en) 2008-04-02
CN101068550A (zh) 2007-11-07
KR101351059B1 (ko) 2014-02-17
EP1904067B1 (en) 2013-11-20
JP5228488B2 (ja) 2013-07-03
CA2588445C (en) 2013-06-25
IL183615A0 (en) 2007-10-31
US20070292504A1 (en) 2007-12-20
WO2006060711A3 (en) 2006-09-08
CA2588445A1 (en) 2006-06-08
BRPI0518781A2 (pt) 2008-12-09
NZ555120A (en) 2009-11-27
EP2586444A1 (en) 2013-05-01
AU2005311652A1 (en) 2006-06-08
RU2007125122A (ru) 2009-01-10
ZA200703866B (en) 2008-03-26
EP2586444B1 (en) 2019-09-25
US8852632B2 (en) 2014-10-07
EP1904067B2 (en) 2017-10-11
AU2005311652B2 (en) 2010-12-02
CN101068550B (zh) 2011-03-30
RU2382648C2 (ru) 2010-02-27
NO20073405L (no) 2007-07-02

Similar Documents

Publication Publication Date Title
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2005086700A3 (en) Hiv integrase inhibitors
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
ATE370948T1 (de) Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
SI1441734T1 (sl) Dihidropirimidin karboksamidni inhibitorji HIV-integraze
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
MD2447F2 (en) Pharmaceutical composition, use thereof and methods of treatment of cephalalgia, migraine, sickness and vomiting
PL370292A1 (en) Formulations for oral administration of active compounds
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
IL179718A0 (en) Pharmaceutical composition containing irbesartan
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
AU2003218130A8 (en) N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
WO2005110414A3 (en) Hiv integrase inhibitors
DE60322919D1 (de) 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen
WO2005013935A3 (en) Composition for releasing a weak base for an extended period of time
MY145885A (en) Controlled release formulations for oral administration
UA87327C2 (ru) Производные бензимидазола, композиция, которая их содержит, их получение и применение
TW200640460A (en) HIV integrase inhibitors
TH59375A3 (th) สูตรผสมทางเภสัช ที่ซึ่งการปลดปล่อยออกได้ถูกควบคุม
NZ720331A (en) Solid pharmaceutical compositions containing an integrase inhibitor

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status